Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme), a biotechnology company that pioneered the use of human hyaluronidase ...

New data presented at AACR supports adding pembrolizumab before and after surgery in patients with newly diagnosed locally ...

Pembrolizumab alone or in combination with chemotherapy can provide long-term benefits over chemotherapy alone in recurrent or metastatic HNSCC, data suggest.

Patients with stage IV ovarian cancer can derive long-term benefits from neoadjuvant pembrolizumab and chemotherapy if they achieve a major pathologic response, according to research published in ...

Research shows improved survival outcomes with statin use in patients with chronic lymphocytic leukemia receiving ibrutinib ...

The addition of neoadjuvant and adjuvant pembrolizumab to standard of care significantly improved outcomes for certain ...

SAN DIEGO - Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology firm specializing in drug delivery technology, has filed a lawsuit against pharmaceutical giant Merck Sharp & Dohme Corp ...

Below-normal snowfall across continental Europe this past winter is depriving regional utilities of a critical source of ...

SAN DIEGO - Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology firm specializing in drug delivery technology, has filed a lawsuit against pharmaceutical giant Merck Sharp & Dohme Corp. for ...

These forward-looking statements also include statements with respect to Halozyme's patent infringement suit against Merck Sharp & Dohme, Corp., to enforce Halozyme's patent rights, including ...